IL1B and COVID-19: Consequently, several drugs/compounds targeting IL-1β or IL-6 have been evaluated in several phase 3 clinical trials each (NCT04372186, NCT04409262, NCT04678739, NCT04364009, NCT04443881 and NCT04324021) as therapeutic option of SARS-CoV-2 infection to treat or prevent severe COVID-19 evaluated.